Veeva Systems (VEEV) Stock
Cloud software platform for life sciences companies. Here's the price, business snapshot, and what's worth knowing about Veeva Systems in October 2026.
Veeva Systems (VEEV) is a cloud‑software company focused on the life sciences industry, providing CRM, clinical, regulatory, quality and data platforms designed for pharmaceutical, biotech and medical‑device firms. It operates a subscription‑based model with high recurring revenue, which has supported steady margins and cash generation as the sector digitises. Key growth drivers include continued R&D outsourcing, regulatory complexity that favours specialised vendors, international expansion and cross‑selling of new modules to existing customers. Investors should note Veeva’s exposure to the healthcare sector and customer concentration in large pharma, which can amplify cyclicality. The shares currently reflect a premium for software‑like margins and growth; valuation and future revenue growth are important to watch. This is general information, not personal financial advice — returns can be volatile and past performance is not a guarantee. Consider whether the company’s sector concentration and valuation fit your risk tolerance and investment horizon.
Why It’s Moving
Veeva Accelerates AI Integration with Global Data Standardization and New Clinical Automation Tools
- Servier adopted Veeva OpenData globally across more than 80 countries, establishing an AI-ready data foundation that highlights growing enterprise reliance on Veeva's standardized reference data.
- The company launched the Veeva Study Builder Agent, an AI solution designed to configure Electronic Data Capture (EDC) and Data Quality System (DQS) builds directly from study protocols, reducing manual work and accelerating clinical study setup.
- Shares closed at $280.68 after moving up 2.12%, outperforming the broader market as investors reacted to these strategic product announcements and partnership wins.
Veeva Accelerates AI Integration with Global Data Standardization and New Clinical Automation Tools
- Servier adopted Veeva OpenData globally across more than 80 countries, establishing an AI-ready data foundation that highlights growing enterprise reliance on Veeva's standardized reference data.
- The company launched the Veeva Study Builder Agent, an AI solution designed to configure Electronic Data Capture (EDC) and Data Quality System (DQS) builds directly from study protocols, reducing manual work and accelerating clinical study setup.
- Shares closed at $280.68 after moving up 2.12%, outperforming the broader market as investors reacted to these strategic product announcements and partnership wins.
Sixth Month Growth Performance
When is the next earnings date for VEEVA SYSTEMS INC (VEEV)?
Veeva Systems has not yet confirmed a specific date for its next earnings release. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous quarter's close, the upcoming report is expected in late November 2026. This scheduled disclosure will cover financial results for the third quarter of fiscal year 2027. Investors should monitor official announcements for the precise timing and market availability details.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Veeva's stock with a target price of $278.22, indicating growth potential.
Financial Health
Veeva Systems is performing well, generating solid profits and cash flow while maintaining strong revenue.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue model
Subscription contracts create predictable revenue and strong margins, though future growth depends on new customer wins and cross‑selling to existing clients.
Global pharma footprint
Veeva benefits from long relationships with major pharmaceutical companies and international expansion, but customer concentration can increase sector sensitivity.
Product innovation focus
Ongoing investment in specialised modules and data services supports cross‑sell opportunities, though competition and regulatory changes can affect adoption rates.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
